Recurrent Adult Primary Liver Cancer
35
0
1
24
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
15 trials with published results (43%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
20.0%
7 terminated out of 35 trials
77.4%
-9.1% vs benchmark
3%
1 trials in Phase 3/4
63%
15 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (35)
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer